Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Characterizing bridging strategies for CAR T-cell therapy

Karlo Perica • 1 Jun 2019
ASCO 2019
Acute Lymphoblastic Leukemia

Karlo Perica, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, explains the rationale behind a retrospective review of adult patients with R/R acute lymphoblastic leukemia (ALL) treated with 19-28z CAR-T therapy seeking to characterize bridging strategies. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Karlo Perica

3:12
CAR-T for ALL: the impact of bridging therapy
Karlo Perica • 1 Jun 2019
1:00
CAR-T for ALL: bridging options and choices
Karlo Perica • 1 Jun 2019

Related Videos

4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
5:14
Is transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals